120 related articles for article (PubMed ID: 25855543)
1. [Impact of a Decree on ACE inhibitors/ARBs in cardiovascular secondary prevention in the Lazio Region (Central Italy): a pre-post analysis].
Mayer F; Kirchmayer U; Di Martino M; Agabiti N; Fusco D; Davoli M
Epidemiol Prev; 2015; 39(1):19-27. PubMed ID: 25855543
[TBL] [Abstract][Full Text] [Related]
2. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
Baker A; Chen LC; Elliott RA; Godman B
BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
4. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
Huang SH; Hsu CN; Yu SH; Cham TM
BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
[TBL] [Abstract][Full Text] [Related]
5. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
[TBL] [Abstract][Full Text] [Related]
6. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
9. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
Potier L; Roussel R; Elbez Y; Marre M; Zeymer U; Reid CM; Ohman M; Eagle KA; Bhatt DL; Steg PG;
Heart; 2017 Sep; 103(17):1339-1346. PubMed ID: 28285267
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Concurrent Prescribing of ACE-Is and ARBs among Beneficiaries of Puerto Rico's Government-Sponsored Health Care Plan During 2012 and 2013.
Figueroa-Ríos D; Hernández-Muñoz JJ; García-Albarrán A; García-Rodríguez EA; Méndez-Hernández G; Vélez-Rivera SM
P R Health Sci J; 2017 Jun; 36(2):71-76. PubMed ID: 28622402
[TBL] [Abstract][Full Text] [Related]
12. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
Walker AM; Liang C; Clifford CR; Parker C; Feldman A
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):348-56. PubMed ID: 24375940
[TBL] [Abstract][Full Text] [Related]
13. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
14. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
.
Kang HB; Choi M; Yoon SG; Cho YS; Je NK
Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
16. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
[TBL] [Abstract][Full Text] [Related]
18. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period.
Almadfaa RO; Wigle PR; Hincapie AL; Guo JJ
Int J Cardiol; 2023 Jan; 370():412-418. PubMed ID: 36306953
[TBL] [Abstract][Full Text] [Related]
19. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
20. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
